Alyeska Investment Group
JANX icon

Alyeska Investment Group’s Janux Therapeutics JANX Stock Holding History

Alyeska Investment Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3M Buy
1,647,140
+46,051
+3% +$667K 0.07% 304
2026
Q1 		$22.3M Buy
1,601,089
+300,000
+23% +$4.11M 0.06% 313
2025
Q4 		$18M Buy
1,301,089
+876,244
+206% +$20.6M 0.05% 326
2025
Q3 		$10.4M Buy
424,845
+166,167
+64% +$4.05M 0.03% 370
2025
Q2 		$5.98M Sell
258,678
-150,000
-37% -$3.95M 0.02% 401
2025
Q1 		$11M Buy
408,678
+63,762
+18% +$2.4M 0.04% 302
2024
Q4 		$18.5M Buy
344,916
+141,732
+70% +$7.5M 0.07% 268
2024
Q3 		$9.23M Buy
203,184
+3,800
+2% +$165K 0.05% 302
2024
Q2 		$8.35M Buy
199,384
+6,338
+3% +$298K 0.05% 291
2024
Q1 		$7.27M Sell
193,046
-4,444
-2% -$96.8K 0.04% 303
2023
Q4 		$2.12M Buy
197,490
+22,490
+13% +$194K 0.01% 367
2023
Q3 		$1.76M Buy
+175,000
New +$2.02M 0.01% 394

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Alyeska Investment Group's JANX Position: Q2 2026 in Review

Alyeska Investment Group increased its Janux Therapeutics (JANX) stake by 2.9% in Q2 2026, buying an estimated $667K and bringing the position to 1,647,140 shares worth $25.3M. The position accounts for 0.07% of the portfolio, ranked #304.

Alyeska Investment Group first reported a position in JANX in Q3 2023 and has held it in 12 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Alyeska Investment Group held 1,647,140 shares of Janux Therapeutics worth $25.3M as of Q2 2026.
  • Alyeska Investment Group bought 46,051 Janux Therapeutics shares in Q2 2026, an estimated $667K.
  • Janux Therapeutics made up 0.07% of Alyeska Investment Group's portfolio in Q2 2026, its #304 holding.
  • Alyeska Investment Group first reported a position in Janux Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.